QPS forms alliance with Taiwan's Development Center for Biotechnology

QPS, a US-based GLP-compliant contract research organisation providing testing services to support preclinical and clinical r&d, has formed an alliance with Taiwan's Development Center for Biotechnology (DCB). DCB is a non-profit organisation supported primarily by government funding to advance Taiwan's biotech industry.

The alliance will give biopharmaceutical firms access to drug development services from preclinical through to clinical. In conjunction with DCB, QPS's current services will be expanded into chemistry, manufacturing and controls (CMC), in vitro/in vivo toxicology and pharmacology.

The recently passed Taiwan Biotechnology Takeoff Package has also paved the way for the expansion of DCB's services to cover process development and cGMP production of biopharmaceuticals.

QPS currently operates a state-of-the-art bioanalytical LC/MS/MS facility in Taipei, Taiwan.

"Our partnership with DCB provides QPS with access to enhanced service offerings, not only to our clients in the Asia-Pacific Rim region, but also around the world," said Ben Chien, ceo and founder of QPS.

"We now have the ability to expand our services to cover preclinical through to clinical with even more efficiencies of scale to increase speed and reduce costs while maintaining our focus on accuracy of data."

DCB now positions itself as a "preclinical value-adding r&d centre for biopharmaceuticals" in Taiwan's drug development value-chain.

"Our organisation has been collaborating with QPS on a project-by-project basis. The new strategic alliance with QPS will not only provide complete and integrated international standard preclinical testing services to domestic and pharmaceutical companies, but also lead to new clients and expanded business opportunities for DCB in the international drug development arena," said DCB president Dr Chia-Lin Jeff Wang.